

WE DELIVER HEALTH


Half-year Report February to July 2022

CONTENTS


2	The first half-year at a glance
3	Interim group management report
3	Business and economic environment
5	Risks and opportunities
5	Forecast
6	Interim condensed consolidated financial statements
7	Consolidated income statement
7	Consolidated statement of comprehensive income
8	Consolidated statement of financial position
9	Consolidated statement of cash flows
10	Consolidated statement of changes in equity
11	Notes to the interim condensed consolidated financial statements
20	Financial calendar 2022/Imprint

This interactive PDF is optimised for use with Adobe Acrobat. Linked tables of contents ensure easy navigation. In addition, the following function buttons can be used:


 Main table of contents

 Last page viewed

 Search

 Previous page

 Next page

 Page reference

THE FIRST HALF-YEAR AT A GLANCE

Key figures of the PHOENIX group in EUR m	1st half-year 2021/22	1st half-year 2022/23
Total operating performance	18,942.9	20,831.1
Revenue	14,816.2	16,178.6
Total income	1,559.3	1,695.8
EBITDA before significant one-off effects	341.7	328.9
EBITDA	308.8	328.9
EBIT	167.0	182.7
Profit before tax before significant one-off effects	165.2	135.0
Profit before tax	132.3	135.0
Profit after tax	98.5	98.6

Key figures of the PHOENIX group		31 July 2021	31 January 2022	31 July 2022
Equity	in EUR m	3,057.0	3,168.2	3,249.7
Equity ratio	in %	29.4	29.5	29.9
Net debt	in EUR m	2,156.1	1,829.8	1,834.6

- Total operating performance and revenue have increased again
- Profit before tax at prior year’s level
- Further reduction in net debt compared to the first half-year 2021/22

The first half-year at a glance

Interim group management report

- Business and economic environment
- Risks and opportunities
- Forecast

Interim condensed consolidated financial statements

- Consolidated income statement
- Consolidated statement of comprehensive income
- Consolidated statement of financial position
- Consolidated statement of cash flows
- Consolidated statement of changes in equity
- Notes to the interim condensed consolidated financial statements

Financial calendar 2022/Imprint

INTERIM GROUP MANAGEMENT REPORT

BUSINESS AND ECONOMIC ENVIRONMENT

Development of the market

The European economy grew in the second quarter of 2022. In the eurozone, seasonally adjusted GDP increased by 4.0% in the second quarter of 2021 compared to the prior year's second quarter. In Germany, the seasonally and calendar-adjusted GDP increased significantly by 1.4% compared to the second quarter of 2021.

Overall, the European pharmaceutical markets continued their moderate growth trend in the first half-year of 2022. The German pharmaceutical market also showed growth. The total turnover of the German wholesale pharmaceutical market grew by 7.5% from January to July 2022 compared to the same period of the prior year. The increase was mainly due to higher prescription pharmaceuticals revenues. Market growth was also noted in various foreign markets of the PHOENIX group.

In total, the PHOENIX group continued its positive development in the European market environment.

Acquisitions

In the first half-year of 2022/23, business combinations led to a cash outflow of EUR 42.7m (comparative period: EUR 15.5m). The acquisitions mostly pertained to pharmacies in several countries.

Results of operations

Compared with the half-year of the financial year 2021/22 total operating performance increased by 10.0% to EUR 20,831.1m in the first six months of 2022/23. This comprises revenue and handled volume. Adjusted for foreign exchange rate effects, total operating performance grew by 9.9%. Revenue grew by EUR 1,362.4m (9.2%) to EUR 16,178.6m (comparative period: EUR 14,816.2m). Adjusted for foreign exchange rate effects, revenue grew by 9.0%.

Gross profit increased by EUR 137.2m to EUR 1,680.0m. The gross profit margin came to 10.4% (comparative period: 10.4%).

Personnel expenses increased by 8.2% to EUR 871.6m (comparative period: EUR 805.4m). This was mainly due to the impact of collective salary increases, acquisitions, and the growth in business.

Other expenses rose by EUR 49.5m to EUR 494.1m, mainly due to increased transport costs, energy costs, IT expenses and higher expenses for other taxes. In relation to revenue, other expenses came to 3.1% (comparative period: 3.0%).

Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased from EUR 308.8m to EUR 328.9m. In connection with COVID-19, costs related to inventory measurement of EUR – 32.9m were recognised in the first six months of the comparative period 2021/22. Adjusted for this one-off effect, EBITDA came to EUR 328.9m and was below the prior year's level (EUR 341.7m).

Depreciation and amortisation came to EUR 146.1m and were slightly above the prior year's level due to acquisitions.

The financial result decreased by EUR 13.1m from EUR – 34.6m in the comparative period to EUR – 47.7m. The decrease is mainly due to a lower net interest result.

The effective tax rate in the first half-year of 2022/23 came to 27.0% and was 25.6% in the comparative period.

Profit after tax came to EUR 98.6m (comparative period: EUR 98.5m).

The first half-year at a glance

Interim group management report

Business and economic environment

Risks and opportunities

Forecast

Interim condensed consolidated financial statements

Consolidated income statement

Consolidated statement of comprehensive income

Consolidated statement of financial position

Consolidated statement of cash flows

Consolidated statement of changes in equity

Notes to the interim condensed consolidated financial statements

Financial calendar 2022/Imprint

Net assets

The group's total assets increased slightly by 1.0% to EUR 10,867.5m compared to 31 January 2022. The currency translation difference on the total assets, which is presented in the statement of changes in equity, amounts to EUR – 110.1m (31 January 2022: EUR – 99.9m).

Non-current assets decreased slightly from EUR 3,886.2m as of 31 January 2022 to EUR 3,853.7m. The intangible assets contain goodwill in the amount of EUR 1,453.2m (31 January 2022: EUR 1,440.4m).

Inventories increased compared to 31 January 2022 by EUR 108.7m to EUR 2,805.5m.

Trade receivables increased by 12.2% to EUR 3,285.5m. As of 31 July 2022, receivables of EUR 89.1m (31 January 2021: EUR 125.6m) had been sold under ABS and factoring programmes that are not accounted for in the statement of financial position. Under ABS and factoring programmes that are accounted for only to the extent of the continuing involvement, receivables of EUR 134.9m had been sold as of 31 July 2022 (31 January 2022: EUR 174.6m). The group's continuing involvement came to EUR 6.0m (31 January 2022: EUR 7.1m).

Other current financial assets decreased from EUR 97.6m as of 31 January 2022 to EUR 87.9m and mainly include loans granted to customers of EUR 22.3m (31 January 2022: EUR 27.5m), as well as receivables from factoring and ABS transactions of EUR 22.8m (31 January 2021: EUR 28.7m).

Other current assets came to EUR 155.9m (31 January 2022: EUR 159.7m).

The change in cash and cash equivalents is presented in the statement of cash flows.

Financial position

Equity increased by EUR 81.5m compared to 31 January 2022. The equity ratio as of 31 July 2022 came to 29.9% (31 January 2022: 29.5%).

Cash flow from operating activities came to EUR 125.5m (comparative period: EUR – 130.6m). Prior year's cash outflow contained an outflow of EUR 158.7m due to the switch from an ABS programme to recognition in the statement of financial position. Cash flow from investing activities came to EUR – 117.3m and was EUR – 75.3m in the comparative period.

Non-current financial liabilities came to EUR 1,589.1m (31 January 2022: EUR 1,795.4m). This item includes lease liabilities according to IFRS 16 of EUR 635.0m (31 January 2022: EUR 658.6m). Beyond that, non-current financial liabilities contain, among others, bonds of EUR 397.0m (31 January 2022: EUR 396.6m) and promissory notes of EUR 356.1m (31 January 2022: EUR 494.1m).

Current financial liabilities came to EUR 713.7m (31 January 2022: EUR 736.9m) and include lease liabilities according to IFRS 16 of EUR 131.6m (31 January 2022: EUR 132.3m). Beyond that, current financial liabilities contain, among others, liabilities to banks of EUR 129.7m (31 January 2022: EUR 113.4m), liabilities from ABS and factoring agreements in the amount of EUR 283.0m (31 January 2022: EUR 345.0m), as well as other loans amounting to EUR 136.3m (31 January 2022: EUR 121.8m).

The first half-year at a glance

Interim group management report

Business and economic environment

Risks and opportunities

Forecast

Interim condensed consolidated financial statements

Consolidated income statement

Consolidated statement of comprehensive income

Consolidated statement of financial position

Consolidated statement of cash flows

Consolidated statement of changes in equity

Notes to the interim condensed consolidated financial statements

Financial calendar 2022/Imprint

According to the calculation below, net debt increased by EUR 4.8m compared to 31 January 2022 to EUR 1,834.6m.

EUR k	31 January 2022	31 July 2022	Change	Change in %
+ Financial liabilities (non-current)	1,795,412	1,589,061	-206,351	-11.5
./ Derivative financial instruments (non-current)	-43	-17	26	-60.5
+ Financial liabilities (current)	736,935	713,679	-23,256	-3.2
./ Derivative financial instruments (current)	-1,303	-3,366	-2,063	158.3
./ Cash and cash equivalents	-964,985	-659,911	305,074	-31.6
+ Receivables sold in the course of factoring and ABS transactions	292,470	218,021	-74,449	-25.5
./ Factoring receivables	-24,697	-20,105	4,592	-18.6
./ Receivables from ABS programmes	-3,974	-2,730	1,244	-31.3
Net debt	1,829,815	1,834,632	4,817	0.3

Trade payables increased by EUR 320.5m to EUR 4,468.5m.

Overall, the PHOENIX group was able to underline its position in the first half-year of 2022/23 as a leading healthcare provider in Europe.

RISKS AND OPPORTUNITIES

The PHOENIX group has comprehensive planning, approval and reporting structures, as well as an early warning system, which we use to identify, assess, and monitor our opportunities and risks. The opportunities and risks of significance to us are presented extensively in our annual report for fiscal year 2021/22. www.phoenixgroup.eu/en/publications/financial-reports

The risks and opportunities presented in that report are still essentially relevant.

FORECAST

For fiscal year 2022/23, the PHOENIX group expects to further expand its market position in Europe through organic growth and acquisitions and thereby increase revenue slightly above the level of growth of the European pharmaceutical markets. We expect revenue growth in nearly all markets in which we are present.

For fiscal year 2022/23, we forecast profit before tax to be at the level seen in 2021/22.

We also expect a slight increase in the equity ratio.

Given the difficulty of predicting when the acquisition of parts of McKesson's European business activities will be completed, the forecasts do not include any resulting effects on the PHOENIX group's revenue, profit before tax or equity ratio.

The first half-year at a glance

Interim group management report

[Business and economic environment](#)
[Risks and opportunities](#)
[Forecast](#)

Interim condensed consolidated financial statements

Consolidated income statement
 Consolidated statement of comprehensive income
 Consolidated statement of financial position
 Consolidated statement of cash flows
 Consolidated statement of changes in equity
 Notes to the interim condensed consolidated financial statements

Financial calendar 2022/Imprint

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

2022 / 2023

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

**Interim condensed consolidated
financial statements**

Consolidated income statement
Consolidated statement
of comprehensive income
Consolidated statement
of financial position
Consolidated statement of cash flows
Consolidated statement
of changes in equity
Notes to the interim condensed
consolidated financial statements

Financial calendar 2022/Imprint

CONSOLIDATED INCOME STATEMENT

for the first half-year of 2022/23

EUR k	2nd quarter 2021/22	2nd quarter 2022/23	1st half-year 2021/22	1st half-year 2022/23
Revenue	7,502,994	8,188,628	14,816,195	16,178,589
Cost of purchased goods and services	-6,703,325	-7,341,586	-13,273,419	-14,498,564
Gross profit	799,669	847,042	1,542,776	1,680,025
Other operating income	7,722	9,147	16,551	15,815
Personnel expenses	-407,241	-435,779	-805,369	-871,561
Other operating expenses	-225,171	-241,027	-444,569	-494,088
Result from associates and joint ventures	-828	-980	-735	-1,477
Results from other investments	59	62	97	142
Earnings before interest, taxes, depreciation and amortisation (EBITDA)	174,210	178,465	308,751	328,856
Amortisation of intangible assets and depreciation of property, plant and equipment	-71,242	-72,606	-141,801	-146,123
Earnings before interest and taxes (EBIT)	102,968	105,859	166,950	182,733
Interest income	2,410	2,464	6,224	4,500
Interest expense	-18,829	-19,858	-36,857	-44,672
Other financial result	-2,894	-5,766	-3,984	-7,534
Financial result	-19,313	-23,160	-34,617	-47,706
Profit before tax	83,655	82,699	132,333	135,027
Income tax	-21,318	-21,913	-33,877	-36,457
Profit after tax	62,337	60,786	98,456	98,570
thereof attributable to non-controlling interests	8,672	8,876	15,759	16,742
thereof attributable to the shareholders of the parent company	53,665	51,910	82,697	81,828

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the first half-year of 2022/23

EUR k	2nd quarter 2021/22	2nd quarter 2022/23	1st half-year 2021/22	1st half-year 2022/23
Profit after tax	62,337	60,786	98,456	98,570
Items not reclassified to the income statement				
Remeasurement of defined benefit plans	426	8,806	3,228	12,546
Items that may subsequently be reclassified to the income statement				
Currency translation differences	8,380	-1,695	11,022	-10,860
Other comprehensive income, net of taxes	8,806	7,111	14,250	1,686
Total comprehensive income	71,143	67,897	112,706	102,256
thereof attributable to non-controlling interests	8,725	8,659	15,765	16,265
thereof attributable to owners of the parent company	62,418	59,238	96,941	83,991

The first half-year at a glance

Interim group management report

- Business and economic environment
- Risks and opportunities
- Forecast

Interim condensed consolidated financial statements

[Consolidated income statement](#)

[Consolidated statement of comprehensive income](#)

[Consolidated statement of financial position](#)

[Consolidated statement of cash flows](#)

[Consolidated statement of changes in equity](#)

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

CONSOLIDATED STATEMENT OF FINANCIAL POSITION as of 31 July 2022

ASSETS

EUR k	31 Jan 2022	31 July 2022
Non-current assets		
Intangible assets	1,876,485	1,896,334
Property, plant and equipment	1,779,804	1,746,159
Investment property	5,083	4,892
Investments in associates and joint ventures	17,724	12,233
Trade receivables	72	0
Other financial assets	96,512	93,851
Deferred tax assets	106,339	96,068
Income tax receivables	4,192	4,188
	3,886,211	3,853,725
Current assets		
Inventories	2,696,791	2,805,498
Trade receivables	2,928,140	3,285,549
Income tax receivables	18,681	18,165
Other financial assets	97,620	87,886
Other assets	159,745	155,913
Cash and cash equivalents	964,985	659,911
	6,865,962	7,012,922
Non-current assets held for sale	3,905	873
Total assets	10,756,078	10,867,520

EQUITY AND LIABILITIES

EUR k	31 Jan 2022	31 July 2022
Equity		
Issued capital	2,786	2,786
Capital reserves	961,106	961,106
Revenue reserves	2,201,480	2,283,238
Accumulated other comprehensive income	-309,774	-307,611
Equity attributable to the shareholders of the parent company	2,855,598	2,939,519
Non-controlling interests	312,588	310,138
	3,168,186	3,249,657
Non-current liabilities		
Financial liabilities	1,795,412	1,589,061
Trade payables	144	601
Provisions for pensions and similar obligations	300,502	286,460
Other non-current provisions	2,509	2,527
Deferred tax liabilities	154,368	155,294
Other non-current liabilities	1,115	1,576
	2,254,050	2,035,519
Current liabilities		
Financial liabilities	736,935	713,679
Trade payables	4,147,890	4,467,947
Other provisions	36,968	33,301
Income tax liabilities	53,487	35,965
Other liabilities	358,269	331,452
	5,333,549	5,582,344
Liabilities directly associated with assets held for sale	293	0
Total equity and liabilities	10,756,078	10,867,520

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
[Consolidated statement of financial position](#)
Consolidated statement of cash flows
Consolidated statement of changes in equity
Notes to the interim condensed consolidated financial statements

Financial calendar 2022/Imprint



CONSOLIDATED STATEMENT OF CASH FLOWS for the first half-year of 2022/23

EUR k	31 July 2021	31 July 2022
Profit after tax	98,456	98,570
Income taxes	33,877	36,541
Profit before income taxes	132,333	135,111
Adjustments for:		
Interest expenses and interest income	30,633	40,172
Amortisation/depreciation/impairment/write-ups of intangible assets, property, plant and equipment and investment property	141,801	146,123
Result from associates and other investments	638	1,335
Net result from the disposal of assets related to investing activities	542	-1,088
Other non-cash expense and income ¹⁾	95,776	122,496
	401,723	444,149
Interest paid	-34,955	-27,381
Interest received	6,069	4,358
Income taxes paid	-22,424	-47,732
Dividends received	265	3,783
Cash flow before change in assets and liabilities	350,678	377,177
Changes in assets and liabilities, net of effects of changes in the scope of consolidation and other non-cash transactions:		
Change in non-current provisions	-21,406	-18,784
Cash flow before change in operating assets and liabilities	329,272	358,393
Change in inventories	-11,067	-91,769
Change in trade receivables ¹⁾	-288,140	-342,491
Change in trade payables ¹⁾	22,480	330,267
	-276,727	-103,993
Change in other assets and liabilities not related to investing or financing activities	-183,181	-128,899
Change in operating assets and liabilities	-459,908	-232,892
Cash flow from operating activities	-130,636	125,501
Acquisition of consolidated companies and business units, net of cash acquired	-15,463	-42,652
Capital expenditures for intangible assets, property, plant and equipment, and investment property	-64,575	-79,103
Investment in other financial assets and non-current assets	-2,821	-4,008
Cash outflows for investments	-82,859	-125,763

EUR k	31 July 2021	31 July 2022
Cash received from the sale of consolidated companies and business units, net of cash disposed	0	241
Cash received from disposal of intangible assets, property, plant and equipment and investment property	6,283	7,131
Proceeds from other financial assets and non-current assets	1,232	1,099
Cash inflows from realised investments and divestments	7,515	8,471
Cash flow from investing activities	-75,344	-117,292
Cash available for financing activities	-205,980	8,209
Capital increase/repayment	0	0
Capital contribution from/repayment to non-controlling interests	2	-736
Purchase/Sale of treasury shares	0	0
Acquisition of additional shares in already consolidated subsidiaries	-177	-1,251
Proceeds from disposal of interests in subsidiaries without loss of control	14	95
Dividends paid to shareholders of the parent company	0	0
Dividends paid to non-controlling interests	-15,252	-15,164
Proceeds from bond issuance and bank loans	1,773	5,470
Repayment of bonds and bank loans	-235,914	-206,258
Change in bank loans which have a maturity period of 3 months or less	77,137	82,311
Proceeds from the issue of loans from shareholders in the parent company	0	0
Repayment of loans from shareholders in the parent company	0	0
Proceeds from the issue of loans from related parties	50,000	0
Repayment of loans from related parties	-15	-45,000
Change in ABS/Factoring ¹⁾	123,056	-63,952
Change in finance lease	-65,235	-71,330
Change in other financial liabilities	684	2,220
Cash flow from financing activities	-63,927	-313,595
Changes in cash and cash equivalents	-269,907	-305,386
Effect of exchange rate changes on cash and cash equivalents	-177	456
Cash and cash equivalents at the beginning of the period	818,843	964,985
Cash and cash equivalents at the end of the period	548,759	660,055
Less cash and cash equivalents included in assets held for sale	0	-144
Cash and cash equivalents presented in the balance sheet at the end of the period	548,759	659,911

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
[Consolidated statement of cash flows](#)
Consolidated statement of changes in equity
Notes to the interim condensed consolidated financial statements

Financial calendar 2022/Imprint

¹⁾ Prior period adjusted.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY for the first half-year of 2022/23

EUR k	Issued capital	Capital reserves	Revenue reserves	Currency translation differences	Remeasurement of defined benefit plans	Equity attributable to shareholders of the parent company	Non-controlling interests	Total equity
1 February 2021	2,786	961,106	2,023,903	-132,471	-191,639	2,663,685	295,969	2,959,654
Profit after tax			82,697			82,697	15,759	98,456
Accumulated other comprehensive income				11,016	3,228	14,244	6	14,250
Total comprehensive income, net of tax			82,697	11,016	3,228	96,941	15,765	112,706
Changes in the interest of consolidated companies						0	146	146
Dividends						0	-16,963	-16,963
Other transactions with owners			1,203			1,203		1,203
Other changes in equity			-42			-42	338	296
31 July 2021	2,786	961,106	2,107,761	-121,455	-188,411	2,761,787	295,255	3,057,042
1 February 2022	2,786	961,106	2,201,480	-99,902	-209,872	2,855,598	312,588	3,168,186
Profit after tax			81,828			81,828	16,742	98,570
Accumulated other comprehensive income				-10,182	12,345	2,113	-477	1,686
Total comprehensive income, net of tax			81,828	-10,182	12,345	83,991	16,265	100,256
Changes in basis of consolidation			9			9	-178	-169
Changes in the interest of consolidated companies			-434			-434	-1,025	-1,459
Dividends						0	-17,516	-17,516
Other transactions with owners			400			400		400
Other changes in equity			-45			-45	4	-41
31 July 2022	2,786	961,106	2,283,238	-110,084	-197,527	2,939,519	310,138	3,249,657

The first half-year at a glance

Interim group management report

- Business and economic environment
- Risks and opportunities
- Forecast

Interim condensed consolidated financial statements

- Consolidated income statement
- Consolidated statement of comprehensive income
- Consolidated statement of financial position
- Consolidated statement of cash flows
- [Consolidated statement of changes in equity](#)
- Notes to the interim condensed consolidated financial statements

Financial calendar 2022/Imprint

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

as of 31 July 2022

The company

PHOENIX Pharma SE, Mannheim, ("PHOENIX group") is a European healthcare provider and pharmaceuticals distribution group. The PHOENIX group has business activities in 25 European countries. In several countries, the PHOENIX group also operates its own pharmacy chains. The registered office is located in Mannheim, Germany.

Basis of presentation

The interim condensed consolidated financial statements of the PHOENIX group as of 31 July 2022 are prepared on the basis of IAS 34 "Interim Financial Reporting", observing all International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board (IASB), London, and mandatory in the EU as of 31 July 2022, as well as all mandatory interpretations of the International Financial Reporting Standards Interpretation Committee (IFRIC).

The interim condensed consolidated financial statements as of 31 July 2022 of the PHOENIX group were released for publication by the Executive Board of PHOENIX Pharma SE on 9 September 2022.

Significant accounting policies

The accounting policies used to prepare the interim condensed consolidated financial statements are – except where financial reporting standards have been applied for the first time in 2022/23 – essentially consistent with those used in the consolidated financial statements as of 31 January 2022. Standards and interpretations that have been applicable since 1 February 2022 for the first time had the following impacts on the interim financial statements:

The amendments to IFRS 3 update the standard to the extent that the standard is now based on the 2018 Conceptual Framework rather than the 1989 Conceptual Framework. In addition, two supplements were also adopted. When identifying liabilities acquired as part of a business combination, an acquirer also has to apply these rules (instead of the Conceptual Framework) for transactions and similar events within the scope of IAS 37 or IFRIC 21. In addition, it was explicitly

stated that contingent assets acquired as part of a business combination are not to be recognised. There was no significant impact on the assets, liabilities, financial position and financial performance of the PHOENIX group.

The amendments to IAS 37 specify that the "cost of fulfilling a contract" comprises "costs that relate directly to the contract". Costs that relate directly to a contract can either be incremental costs of fulfilling that contract or an allocation of other costs that relate directly to fulfilling contracts. There was no significant impact on the assets, liabilities, financial position and financial performance of the PHOENIX group.

The amendments to IAS 16 have made it inadmissible to deduct income stemming from the sale of goods produced whilst an item of property, plant and equipment is being brought to the location intended by management and in the intended working condition, from the cost of that item of property, plant and equipment. Rather, income from selling such items and the costs for the production of these goods are to be recorded in profit or loss. The cost for test runs to check whether the item of property, plant and equipment works properly, continue to be an example of directly allocable costs. There was no significant impact on the assets, liabilities, financial position and financial performance of the PHOENIX group.

Business combinations

The business combinations carried out in the first six months of 2022/23 are explained below. Purchase accounting is performed in accordance with the acquisition method pursuant to IFRS 3 "Business Combinations".

In fiscal year 2022/23, the cumulative profit after tax of the acquirees came to EUR –22k and revenue to EUR 3,615k. Assuming that the acquisition date coincides with the beginning of the reporting period for all business combinations, accumulated revenue for the period came to EUR 7,281k. Assuming that the acquisition date coincides with the beginning of the reporting period for all business combinations, the accumulated profit after tax came to EUR 348k.

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

The table below shows a summary of the fair values of acquisitions:

Fair value recognised upon acquisition

EUR k	Other
Cash and cash equivalents	12,482
Equity instruments	0
Acquisition-date fair value of previously held equity interest	0
Total cost	12,482
Intangible assets	13
Other non-current assets	163
Inventories	1,077
Trade receivables	1,667
Cash and cash equivalents	1,654
Other current assets	201
Non-current liabilities	345
Current liabilities	2,772
Net assets	1,658
Non-controlling interests	0
Net assets acquired	1,658
Bargain purchase	0
Goodwill	10,824

Other business combinations

In the first six months of 2022/23, the group acquired further pharmacies that are individually immaterial.

The goodwill arising on those acquisitions was allocated to the cash-generating units Norway (EUR 3,129k), Serbia (EUR 2,729k), the Netherlands (EUR 2,122k), Switzerland (EUR 1,601k) and Slovakia (EUR 1,243k) and is managed in the local functional currencies (NOK, RSD, EUR and CHF).

Non-controlling interests were recognised at the proportionate identifiable net assets in the acquirees.

The purchase price allocation takes into account all the information about facts and circumstances as of the acquisition date that was available until the preparation of these financial statements. If further facts or circumstances become known within the 12-month measurement period in accordance with IFRS 3, the purchase price allocation is adjusted accordingly.

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

Revenue

The tables below show a breakdown of revenue within the meaning of IFRS 15 based on the type of goods and services:

1st half-year 2022/23	Trade revenue	Revenue from commissions	Distribution fees and consignment warehouse fees	Other logistic services	Other services	Other revenue	Total revenue within the meaning of IFRS 15
EUR k							
Gross revenue	16,379,577	61,090	54,545	28,027	230,869	146,129	16,900,237
Sales deductions	- 732,538	0	- 20	0	0	- 2	- 732,560
Revenue	15,647,039	61,090	54,525	28,027	230,869	146,127	16,167,677
thereof: Satisfaction of performance obligation at a point in time	15,647,039	57,384	49,426	27,096	215,509	109,451	16,105,905
thereof: Satisfaction of performance obligation over time	0	3,706	5,099	931	15,360	36,676	61,772

Total revenue for the first six months in fiscal year 2022/23 amounts to EUR 16,178.589k and includes revenue from leases of EUR 10.912k.

1st half-year 2021/22	Trade revenue	Revenue from commissions	Distribution fees and consignment warehouse fees	Other logistic services	Other services	Other revenue	Total revenue within the meaning of IFRS 15
EUR k							
Gross revenue	14,967,843	59,378	68,543	29,218	223,419	135,283	15,483,684
Sales deductions	- 678,870	0	- 17	0	0	- 7	- 678,894
Revenue	14,288,973	59,378	68,526	29,218	223,419	135,276	14,804,790
thereof: Satisfaction of performance obligation at a point in time	14,288,973	54,996	64,048	28,350	211,943	101,385	14,749,695
thereof: Satisfaction of performance obligation over time	0	4,382	4,478	868	11,476	33,891	55,095

The first half-year at a glance

Interim group management report

- Business and economic environment
- Risks and opportunities
- Forecast

Interim condensed consolidated financial statements

- Consolidated income statement
- Consolidated statement of comprehensive income
- Consolidated statement of financial position
- Consolidated statement of cash flows
- Consolidated statement of changes in equity
- [Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

Other operating expenses

Other operating expenses contain expenses in connection with ABS and factoring programmes of EUR 872k (comparative period: EUR 981k).

Financial result

EUR k	1st half-year 2021/22	1st half-year 2022/23
Interest income	6,224	4,500
Interest expenses	-36,857	-44,672
Other financial result	-3,984	-7,534
Financial result	-34,617	-47,706

Interest income includes interest from customers of EUR 3,099k (comparative period: EUR 3,468k).

The other financial result includes exchange rate gains of EUR 15,595k (comparative period: EUR 10,968k) and exchange rate losses of EUR 12,626k (comparative period: EUR 5,617k). Changes in the market value of derivatives gave rise to income of EUR 31,572k (comparative period: EUR 23,011k) and expenses of EUR 41,205k (comparative period: EUR 30,486k).

Other assets and other liabilities

EUR k	31 Jan 2022	31 July 2022
Prepayments	75,691	86,677
Tax claims – VAT and other taxes	53,021	35,424
Sundry other assets	31,033	33,812
Other assets	159,745	155,913

EUR k	31 Jan 2022	31 July 2022
VAT and other tax liabilities	82,659	88,988
Personnel liabilities	202,753	174,904
Liabilities relating to social security/similar charges	34,445	32,805
Contract Liabilities (IFRS 15)	20,205	20,722
Sundry other liabilities	18,207	14,033
Other liabilities	358,269	331,452

Other financial assets and other financial liabilities

The table below presents the non-current financial assets:

EUR k	31 Jan 2022	31 July 2022
Trade receivables	72	0
Other financial assets		
Equity and debt instruments	56,799	56,780
Other loans	7,640	6,755
Lease receivables	31,749	29,996
Sundry other financial assets	324	320
	96,512	93,851

The table below presents the current financial assets:

EUR k	31 Jan 2022	31 July 2022
Trade receivables	2,928,140	3,285,549
Other financial assets		
Loans to and receivables from associates	822	163
Other loans	27,525	22,331
Derivative financial instruments	2,697	1,282
Lease receivables	12,706	12,518
ABS/Factoring receivables	28,671	22,835
Sundry other current financial assets	25,199	28,757
	97,620	87,886

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

The receivables from factoring and ABS transactions as of 31 July 2022 are presented below:

EUR k	31 Jan 2022	31 July 2022
Transferred but only partly derecognised receivables		
Receivables not derecognised in accordance with IFRS 9		
Volume of receivables	407,355	354,513
Financial liabilities	336,835	276,555
Continuing involvement		
Volume of receivables	174,622	134,853
Continuing involvement	7,728	5,965
Financial liabilities	8,185	6,396
Transferred and fully derecognised receivables		
Volume of receivables	125,576	89,133
Retentions of title	28,671	22,835

At the reporting date, financial liabilities were divided into non-current and current liabilities as follows:

EUR k	31 Jan 2022	31 July 2022
Financial liabilities (non-current)		
Liabilities to banks	412,641	274,221
Bonds	396,559	397,026
Loans	43	40
Liabilities to associates and related parties	320,000	275,000
Lease liabilities	658,638	635,341
Other financial liabilities	7,531	7,433
	1,795,412	1,589,061

EUR k	31 Jan 2022	31 July 2022
Financial liabilities (current)		
Liabilities to banks	113,367	129,670
Loans	121,765	136,342
Liabilities to associates and related parties	6,785	5,326
ABS and factoring liabilities	345,020	282,951
Lease liabilities	132,322	131,605
Other financial liabilities	17,676	27,785
	736,935	713,679

In connection with the loan agreements, it was agreed to comply with certain financial covenants, all of which were met in the first six months of 2022/23.

Other financial liabilities (non-current) contain non-current derivative financial instruments of EUR 17k (31 January 2022: EUR 43k).

Other financial liabilities (current) contain current derivative financial instruments of EUR 3,366k (31 January 2022: EUR 1,303k).

The first half-year at a glance

Interim group management report

- Business and economic environment
- Risks and opportunities
- Forecast

Interim condensed consolidated financial statements

- Consolidated income statement
- Consolidated statement of comprehensive income
- Consolidated statement of financial position
- Consolidated statement of cash flows
- Consolidated statement of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

Information on financial instruments

The items in the statement of financial position for financial instruments are assigned to classes and categories.

The carrying amounts for each category and class of financial assets, and the fair values for each class are presented in the following table:

31 July 2022	Category pursuant to IFRS 9			Carrying amount	Fair value
	At amortised costs	At fair value through profit and loss	No category according to IFRS 9		
EUR k					
Assets					
Equity and debt instruments	0	56,780	0	56,780	56,780
Trade receivables	2,931,036	354,513	0	3,285,549	3,285,549
Loans to and receivables from associates or related parties	163	0	0	163	163
Other loans	29,086	0	0	29,086	28,970
Derivative financial assets without hedge accounting	0	1,282	0	1,282	1,282
Other financial assets	51,912	0	0	51,912	51,912
Lease receivables	0	0	42,514	42,514	42,514
Cash and cash equivalents	659,911	0	0	659,911	659,911

31 January 2022	Category pursuant to IFRS 9			Carrying amount	Fair value
	At amortised costs	At fair value through profit and loss	No category according to IFRS 9		
EUR k					
Assets					
Equity and debt instruments	0	56,799	0	56,799	56,799
Trade receivables	2,520,857	407,355	0	2,928,212	2,928,212
Loans to and receivables from associates or related parties	822	0	0	822	822
Other loans	35,165	0	0	35,165	35,412
Derivative financial assets without hedge accounting	0	2,697	0	2,697	2,697
Other financial assets	54,194	0	0	54,194	54,194
Lease receivables	0	0	44,455	44,455	44,455
Cash and cash equivalents	964,985	0	0	964,985	964,985

Equity and debt instruments primarily contain shares in unlisted entities and participations in limited partnerships. Shares in listed entities are measured at the quoted price determined as of the reporting date. For other equity and debt instruments, the fair value is determined using a multiplier method (revenue multiple, level 3). This method uses individually derived multipliers between 0.50 and 1.10 (31 January 2022: between 0.50 and 1.10). A 10% increase in the multipliers would increase the value by EUR 6,414k (31 January 2022: EUR 6,414k); a 10% decrease in the multipliers would decrease the value by EUR 6,419k (31 January 2022: EUR 6,419k).

Derivatives are recognised at their fair values (level 2).

Due to the short-term maturities of cash and cash equivalents, trade receivables, and other current financial assets, their carrying amounts generally approximate the fair values at the reporting date (level 2).

The first half-year at a glance

Interim group management report

- Business and economic environment
- Risks and opportunities
- Forecast

Interim condensed consolidated financial statements

- Consolidated income statement
- Consolidated statement of comprehensive income
- Consolidated statement of financial position
- Consolidated statement of cash flows
- Consolidated statement of changes in equity
- [Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

The fair value of loans to and receivables from associates or related entities, other loans, held-to-maturity financial assets and other non-current financial assets due after more than one year correspond to the net present value of the payments related to the assets based on the current interest rate parameters and yield curves (level 2).

The carrying amounts for each category and class of financial liabilities and the fair values for each class are presented in the following table:

31 July 2021	Category pursuant to IFRS 9			Carrying amount	Fair value
	At amortised costs	At fair value through profit and loss	No category according to IFRS 9		
EUR k					
Financial liabilities					
Liabilities to banks	403,891	0	0	403,891	404,229
Bonds	397,026	0	0	397,026	378,608
Loans	136,382	0	0	136,382	136,382
Trade payables	4,468,548	0	0	4,468,548	4,468,548
Liabilities to associates and related parties	280,326	0	0	280,326	280,326
ABS and factoring liabilities	282,951	0	0	282,951	282,951
Other financial liabilities	30,847	988	0	31,835	31,835
Lease liabilities	0	0	766,946	766,946	n/a
Derivative financial liabilities without hedge accounting	0	3,383	0	3,383	3,383

31 January 2022	Category pursuant to IFRS 9			Carrying amount	Fair value
	At amortised costs	At fair value through profit and loss	No category according to IFRS 9		
EUR k					
Financial liabilities					
Liabilities to banks	526,008	0	0	526,008	526,430
Bonds	396,559	0	0	396,559	403,576
Loans	121,808	0	0	121,808	121,808
Trade payables	4,148,034	0	0	4,148,034	4,148,034
Liabilities to associates and related parties	326,785	0	0	326,785	326,785
ABS and factoring liabilities	345,020	0	0	345,020	345,020
Other financial liabilities	22,801	1,060	0	23,861	23,861
Lease liabilities	0	0	790,960	790,960	n/a
Derivative financial liabilities without hedge accounting	0	1,346	0	1,346	1,346

The fair value of the bonds is the nominal value multiplied by the quoted price as of the reporting date (level 1).

Derivatives are recognised at their fair values (level 2).

Due to the short-term maturities of trade payables and other current financial liabilities, their carrying amounts generally approximate the fair values at the reporting date (level 2).

The first half-year at a glance

Interim group management report

- Business and economic environment
- Risks and opportunities
- Forecast

Interim condensed consolidated financial statements

- Consolidated income statement
- Consolidated statement of comprehensive income
- Consolidated statement of financial position
- Consolidated statement of cash flows
- Consolidated statement of changes in equity
- [Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

Fair value hierarchy of financial instruments

The PHOENIX group applies the following fair value hierarchy to define and present its financial instruments measured at fair value:

Level 1: Quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: Techniques that use inputs that are not based on observable market data.

Financial instruments measured at fair value

EUR k	Level 1	Level 2	Level 3	Total
31 July 2022				
Equity and debt instruments	0	0	56,780	56,780
Trade receivables	0	354,513	0	354,513
Derivative financial assets without hedge accounting	0	1,282	0	1,282
Derivative financial liabilities without hedge accounting	0	3,383	0	3,383
Other financial liabilities	0	0	988	988
31 January 2022				
Equity and debt instruments	0	0	56,799	56,799
Trade receivables	0	407,355	0	407,355
Derivative financial assets without hedge accounting	0	2,697	0	2,697
Derivative financial liabilities without hedge accounting	0	1,346	0	1,346
Other financial liabilities	0	0	1,060	1,060

The following table shows the reconciliation of the fair value based on level 3.

EUR k	Equity and debt instruments	Other financial liabilities
1 February 2022	56,799	1,060
Purchase	0	0
Sale of shares	0	0
New measurement (through profit or loss)	0	0
Acquisitions	0	0
Remeasurement of contingent purchase price obligations (through profit or loss)	0	0
Payments due to acquisitions	0	-73
Other	-19	1
31 July 2022	56,780	988

Notes to the statement of cash flows

EUR k	31 Jan 2022	31 July 2022
Restricted cash		
Cash and cash equivalents at the end of the period	964,985	659,911
thereof restricted		
due to security deposits	4,129	1,695
due to restrictions placed upon foreign subsidiaries	47,629	38,312

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity
[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

Related party disclosures

During the reporting period, PHOENIX group acquired a property from a related party for EUR 6,285k. Furthermore, PHOENIX group acquired a business from a related party. The acquisition costs are not final yet.

During the reporting period, a related party granted a loan to PHOENIX group amounting to EUR 55,000k. Interest expenses of EUR 90k were accrued thereon.

Furthermore, the business relationships with related parties presented in the consolidated financial statements as of 31 January 2022 remained essentially unchanged in the first half-year of 2022/23.

Mannheim, 9 September 2022

The Executive Board of PHOENIX Pharma SE

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement
of comprehensive income
Consolidated statement
of financial position
Consolidated statement of cash flows
Consolidated statement
of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2022/Imprint

FINANCIAL CALENDAR 2022

Please consult our calendar for the most important announcement dates:

21 December Quarterly statement February to October 2022

IMPRINT

Publisher

Maren Holoda
Director Corporate Communications
Jacob-Nicolas Sprengel
Senior Manager Corporate Communications

PHOENIX Pharma SE
Corporate Communications
Pfungstweidstrasse 10–12
68199 Mannheim
Germany
Phone +49 (0)621 8505 8502
Fax +49 (0)621 8505 8501
media@phoenixgroup.eu
www.phoenixgroup.eu

Investor Relations

Karsten Loges
Director Corporate Finance
and Asset Management
Phone +49 (0)621 8505 741
k.loges@phoenixgroup.eu

Concept, design and realisation

Corporate Communications PHOENIX group
HGB Hamburger Geschäftsberichte
GmbH & Co. KG, Hamburg, Germany

Translation of the German version.
The German version is binding.

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement
of comprehensive income
Consolidated statement
of financial position
Consolidated statement of cash flows
Consolidated statement
of changes in equity
Notes to the interim condensed
consolidated financial statements

[Financial calendar 2022/Imprint](#)

